SPYRE THERAPEUTICS INC (SYRE) Stock News

USA - Nasdaq - NASDAQ:SYRE - US00773J2024 - Common Stock

30 USD

+0.25 (+0.84%)

Last: 11/28/2025, 8:02:23 PM

30 USD

0 (0%)

After Hours: 11/28/2025, 8:02:23 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SYRE Latest News, Press Relases and Analysis

All

Press Releases

22 days ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

25 days ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

25 days ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

25 days ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

25 days ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

4 months ago - By: The Motley Fool

Spyre (SYRE) Q2 R&D Up 23% Loss Narrows

a month ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

a month ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

a month ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

2 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

2 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

2 months ago - By: Benzinga - Mentions: ERIC ACI DPZ JPM ...

Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday

2 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

2 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

2 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

2 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

2 months ago - By: Benzinga - Mentions: IVA YCBD IMAB IMTX ...

12 Health Care Stocks Moving In Friday's After-Market Session

2 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

2 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

2 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

3 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases

6 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

6 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

6 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

6 months ago - By: Zacks Investment Research

Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know

6 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

7 months ago - By: Zacks Investment Research

How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%

7 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

7 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

7 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

8 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

9 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

9 months ago - By: Spyre Therapeutics, Inc.

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update